721927-59-9

Basic information

• Product Name: Carbamic acid, [(1S)-2-hydroxy-1-(methoxymethyl)ethyl]-, 1,1-dimethylethyl
• Synonyms: Carbamic acid, [(1S)-2-hydroxy-1-(methoxymethyl)ethyl]-, 1,1-dimethylethyl;N-Boc-(S)-2-amino-3-methoxy-1-propanol;TERT-BUTYL (S)-(1-HYDROXY-3-METHOXYPROPAN-2-YL)CARBAMATE
• CAS NO: 721927-59-9
• Molecular Formula: C9H19NO4
• Molecular Weight: 205.25146
• Product Categories: N-BOC
• Mol File: 721927-59-9.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, [(1S)-2-hydroxy-1-(methoxymethyl)ethyl]-, 1,1-dimethylethyl(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-2-hydroxy-1-(methoxymethyl)ethyl]-, 1,1-dimethylethyl(721927-59-9)
• EPA Substance Registry System: Carbamic acid, [(1S)-2-hydroxy-1-(methoxymethyl)ethyl]-, 1,1-dimethylethyl(721927-59-9)

Safety Data

• Hazardous Substances Data: 721927-59-9(Hazardous Substances Data)

Upstream product

• 108149-63-9 4-hydroxymethyl-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 856417-65-7 2-((tert-butoxycarbonyl)amino)-3-methoxypropanoic acid 
• 51293-47-1 N-tert-butoxycarbonyl-(S)-O-methyl-serin 
• 24424-99-5 di-tert-butyl dicarbonate 
• 134167-07-0 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-methoxypropanoate 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 543-27-1 isobutyl chloroformate 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 183793-48-8 ((S)-2-Benzyloxy-1-methoxymethyl-ethyl)-carbamic acid tert-butyl ester 
• 862372-14-3 methyl (R)-2-(tert-butoxycarbonylamino)-3-methoxypropanoate 
• 95715-86-9 (S)-2,2-dimethyl-oxazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 4-methyl ester 
• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 
• 1332856-11-7 C₁₆H₂₅NO₄ 
• 79069-15-1 N-(tert-butyloxycarbonyl)-O-benzyl-L-serinol 

Relevant articles and documents

ERK INHIBITOR AND USE THEREOF

Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.

Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)

The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated kinases (ERK1 and ERK2) serve as central nodes within this pathway. The feasibility of targeting the RAS/MAPK pathway has been demonstrated by the clinical responses observed through the use of BRAF and MEK inhibitors in BRAF V600E/K metastatic melanoma; however, resistance frequently develops. Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma. We describe our structure-based design approach leading to the discovery of AZD0364, a potent and selective inhibitor of ERK1 and ERK2. AZD0364 exhibits high cellular potency (IC50 = 6 nM) as well as excellent physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties and has demonstrated encouraging antitumor activity in preclinical models.

DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER

The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.